Novavax Shares Are Trading Higher After the Company Reported the Results From Its Phase 3 PREVENT-19 Trial Achieved Its Pre-specified Endpoint and the Results Form Its Study 307 Met Its Primary Endpoint.
Novavax Shares Are Trading Higher After the Company Reported the Results From Its Phase 3 PREVENT-19 Trial Achieved Its Pre-specified Endpoint and the Results Form Its Study 307 Met Its Primary Endpoint.
在该公司报告其第3阶段预防-19试验的结果达到了预先指定的终点，以及其研究307达到其主要终点后，Novavax的股价上涨。
Novavax shares are trading higher after the company reported the results from its Phase 3 PREVENT-19 trial achieved its pre-specified endpoint and the results form its Study 307 met its primary endpoint.
Novavax股价上涨，此前该公司报告称，其3期预防-19试验的结果达到了预先指定的终点，其研究307的结果达到了主要终点。
资讯热榜
更新时间